The drastic cost-cutting move followa the deaths of two teenagers that forced the company to restrict usage of its gene ...

Key Takeaways Shares of drug developer Sarepta Therapeutics jumped in extended trading Wednesday after the company unveiled a major restructuring plan.The plan involves cutting 36% of its workforce ...

The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.

The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.

This is a developing story and will be updated as more information becomes available. | Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, ...

Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock soared 36% in after-hours trading Wednesday after the biotech company announced a major strategic restructuring plan designed to ensure ...

Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover ...

Sarepta is facing a shareholder lawsuit over ELEVIDYS-related deaths. Robbins LLP cites safety risks and stock losses.

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug ...